Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis

被引：8

作者：

Zhang, Liulu ^{[1
]}

Chen, Yuanqi ^{[1
,2
]}

Cheng, Min-Yi ^{[1
]}

Zhuang, Xiaosheng ^{[3
]}

Zou, Jiachen ^{[1
]}

Wei, Dannuo ^{[4
]}

Lin, Ying-Yi ^{[1
]}

Zhang, Yi ^{[1
]}

Wang, Kun ^{[1
]}

机构：

[1] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Breast Canc, Ctr Canc, 106 Zhongshan Er Rd, Guangzhou 510080, Peoples R China

[2] Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China

[3] Chinese Univ Hong Kong, Sch Life Sci, Dept Cell & Mol Biol, Shatin, Hong Kong, Peoples R China

[4] Univ Hong Kong, Dept Social Work & Social Adm, Pokfulam, Hong Kong, Peoples R China

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2022年 / 14卷

基金：

中国国家自然科学基金;

关键词：

homologous recombination deficiency; platinum-based chemotherapy; triple-negative breast cancer; PATHOLOGICAL COMPLETE RESPONSE; PHASE-II; CARBOPLATIN; DOXORUBICIN; CYCLOPHOSPHAMIDE; GEMCITABINE; SENSITIVITY; GEPARSIXTO; CISPLATIN; REPAIR;

D O I：

10.1177/17588359221096253

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Recent studies have shown that homologous recombination deficiency (HRD) may be correlated with the pathological complete response (pCR) rate. This meta-analysis aimed to determine the predictive value of HRD for the pCR rate in patients with triple-negative breast cancer (TNBC) receiving platinum-based neoadjuvant chemotherapy (NCT). Methods: Published articles were searched in the PubMed, Embase, Medline, Web of Science, and Cochrane databases up to 1 June 2021, and studies reporting the pCR rate for HRD carriers on platinum-based NCT were selected. Odds ratios (ORs) with 95% confidence intervals (CIs) were determined for the pCR rate, clinical response rate, and Grade 3 or higher adverse events (AEs) using the random-effects model. Bias risk was evaluated using the Cochrane Collaboration tool (PROSPERO, registration number CRD42021249874). Results: Seven studies were eligible. The results showed that HRD carriers had higher pCR rates than non-HRD carriers across all treatment arms (OR = 3.84, 95% CI = [1.93, 7.64], p = 0.0001). Among HRD carriers, the pCR rate was higher in patients on platinum-based NCT than in those without platinum exposure (OR = 1.95, 95% CI = [1.17, 3.23], p = 0.01). We did not observe marked pCR improvements in non-HRD carriers. Among HRD carriers, the pCR rates in the mutant and wild-type breast cancer susceptibility gene (BRCA) groups did not differ significantly (OR = 2.00, 95% CI = [0.77, 5.23], p = 0.16), but HRD carriers with wild-type BRCA had a significant advantage over non-HRD carriers on platinum-based NCT (OR = 3.64, 95% CI = [1.83, 7.21], p = 0.0002). Conclusion: HRD is an effective predictor of increased pCR rates in platinum-based NCT, especially in wild-type BRCA patients. Adding platinum to NCT for non-HRD carriers can increase the incidence of AEs but may not improve the therapeutic effect.

引用

页数：14

共 42 条

[1] Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer [J].

Abkevich, V. ;

Timms, K. M. ;

Hennessy, B. T. ;

Potter, J. ;

Carey, M. S. ;

Meyer, L. A. ;

Smith-McCune, K. ;

Broaddus, R. ;

Lu, K. H. ;

Chen, J. ;

Tran, T. V. ;

Williams, D. ;

Iliev, D. ;

Jammulapati, S. ;

FitzGerald, L. M. ;

Krivak, T. ;

DeLoia, J. A. ;

Gutin, A. ;

Mills, G. B. ;

Lanchbury, J. S. .

BRITISH JOURNAL OF CANCER, 2012, 107 (10) :1776-1782

[2]

Alli Elizabeth, 2011, BMC Pharmacology, V11, P7, DOI 10.1186/1471-2210-11-7

[3] Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents [J].

Birkbak, Nicolai J. ;

Wang, Zhigang C. ;

Kim, Ji-Young ;

Eklund, Aron C. ;

Li, Qiyuan ;

Tian, Ruiyang ;

Bowman-Colin, Christian ;

Li, Yang ;

Greene-Colozzi, April ;

Iglehart, J. Dirk ;

Tung, Nadine ;

Ryan, Paula D. ;

Garber, Judy E. ;

Silver, Daniel P. ;

Szallasi, Zoltan ;

Richardson, Andrea L. .

CANCER DISCOVERY, 2012, 2 (04) :366-375

[4] A basic introduction to fixed-effect and random-effects models for meta-analysis [J].

Borenstein, Michael ;

Hedges, Larry V. ;

Higgins, Julian P. T. ;

Rothstein, Hannah R. .

RESEARCH SYNTHESIS METHODS, 2010, 1 (02) :97-111

[5] The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis [J].

Caramelo, Olga ;

Silva, Cristina ;

Caramelo, Francisco ;

Frutuoso, Cristina ;

Almeida-Santos, Teresa .

HEREDITARY CANCER IN CLINICAL PRACTICE, 2019, 17 (1)

[6] Homologous recombination deficiency (HRD) as a predictive biomarker of response to preoperative systemic therapy (PST) in TBCRC008 comprising a platinum in HER2-negative primary operable breast cancer [J].

Connolly, R. ;

Elkin, E. ;

Timms, K. ;

Goetz, M. ;

Boughey, J. ;

Zhang, Z. ;

Walsh, B. ;

Carpenter, J. ;

Storniolo, A. ;

Watkins, S. ;

Gabrielson, E. ;

Hartman, A-R ;

Stearns, V. .

CANCER RESEARCH, 2016, 76

[7] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[8] Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions [J].

Cumpston, Miranda ;

Li, Tianjing ;

Page, Matthew J. ;

Chandler, Jacqueline ;

Welch, Vivian A. ;

Higgins, Julian P. T. ;

Thomas, James .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (10)

[9] Bias in meta-analysis detected by a simple, graphical test [J].

Egger, M ;

Smith, GD ;

Schneider, M ;

Minder, C .

BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634

[10] Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) [J].

Fasching, P. A. ;

Link, T. ;

Hauke, J. ;

Seither, F. ;

Jackisch, C. ;

Klare, P. ;

Schmatloch, S. ;

Hanusch, C. ;

Huober, J. ;

Stefek, A. ;

Seiler, S. ;

Schmitt, W. D. ;

Uleer, C. ;

Doering, G. ;

Rhiem, K. ;

Schneeweiss, A. ;

Engels, K. ;

Denkert, C. ;

Schmutzler, R. K. ;

Hahnen, E. ;

Untch, M. ;

Burchardi, N. ;

Blohmer, J-U ;

Loibl, S. .

ANNALS OF ONCOLOGY, 2021, 32 (01) :49-57

← 1 2 3 4 5 →